We are live on ! Find out more
DBG

De Burlo Group Portfolio holdings

AUM $441M
1-Year Est. Return 21.21%
This Fund
S&P 500
This Quarter Est. Return
-6.47%
1 Year Est. Return
+21.21%
3 Year Est. Return
+98.05%
5 Year Est. Return
+220.33%
10 Year Est. Return
+1,846.98%
AUM
$445M
AUM Growth
-$87.7M
Cap. Flow
-$104M
Cap. Flow %
-23.3%
Top 10 Hldgs %
44.55%
Holding
123
New
13
Increased
19
Reduced
43
Closed
33

Top Buys

Rank Stock Value
1
PG icon
Procter & Gamble
PG
+$12.7M
2
MRK icon
Merck
MRK
+$11.3M
3
VZ icon
Verizon
VZ
+$10.3M
4
SBUX icon
Starbucks
SBUX
+$7.1M
5
EEFT icon
Euronet Worldwide
EEFT
+$6.91M

Top Sells

Rank Stock Value
1
TEAM icon
Atlassian
TEAM
+$15M
2
FTNT icon
Fortinet
FTNT
+$11.9M
3
AMZN icon
Amazon
AMZN
+$8.98M
4
SIVB
SVB Financial Group
SIVB
+$8.35M
5
CNC icon
Centene
CNC
+$8.34M

Sector Composition

Rank Sector Weight
1 Healthcare 27.45%
2 Financials 26.95%
3 Technology 16.16%
4 Consumer Discretionary 9.02%
5 Consumer Staples 8.97%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
STE icon
26
Steris
STE
$20.5B
$5.87M 1.32%
54,950
+49,000
+824% +$5.47M
INTC icon
27
Intel
INTC
$504B
$5.57M 1.25%
118,691
+108,000
+1,010% +$5.06M
CCI icon
28
Crown Castle
CCI
$32.5B
$4.96M 1.11%
45,650
+29,300
+179% +$3.22M
GHDX
29
DELISTED
Genomic Health, Inc.
GHDX
$4.74M 1.06%
73,600
+26,700
+57% +$1.87M
CI icon
30
Cigna
CI
$75.7B
$4.72M 1.06%
+24,850
New +$5.18M
AMED
31
DELISTED
Amedisys
AMED
$4.5M 1.01%
38,450
-14,800
-28% -$1.74M
TJX icon
32
TJX Companies
TJX
$170B
$4.41M 0.99%
98,500
-85,900
-47% -$4.34M
PGR icon
33
Progressive
PGR
$120B
$3.75M 0.84%
62,200
-62,300
-50% -$4.14M
CIEN icon
34
Ciena
CIEN
$57.7B
$3.7M 0.83%
+109,000
New +$3.45M
AMT icon
35
American Tower
AMT
$76.7B
$3.63M 0.81%
22,920
-200
-0.9% -$31.3K
CSX icon
36
CSX Corp
CSX
$98.1B
$3.6M 0.81%
174,000
-121,500
-41% -$2.79M
ALGN icon
37
Align Technology
ALGN
$12B
$3.38M 0.76%
16,145
-32,650
-67% -$8.25M
ANET icon
38
Arista Networks
ANET
$222B
$3.36M 0.76%
255,520
-3,200
-1% -$46K
ABBV icon
39
AbbVie
ABBV
$454B
$3.26M 0.73%
35,350
-200
-0.6% -$17.6K
BDX icon
40
Becton Dickinson
BDX
$42.1B
$3.21M 0.72%
14,603
-4,510
-24% -$1.05M
HRC
41
DELISTED
HILL-ROM HOLDINGS, INC.
HRC
$3.19M 0.72%
+36,000
New +$3.27M
DHR icon
42
Danaher
DHR
$135B
$3.1M 0.7%
33,896
ABMD
43
DELISTED
Abiomed Inc
ABMD
$2.99M 0.67%
9,200
-100
-1% -$34.7K
MOH icon
44
Molina Healthcare
MOH
$10.4B
$2.83M 0.64%
+24,400
New +$3.2M
EW icon
45
Edwards Lifesciences
EW
$48.3B
$2.79M 0.63%
54,600
-900
-2% -$45.5K
ULTA icon
46
Ulta Beauty
ULTA
$20.5B
$2.73M 0.61%
11,150
-15,600
-58% -$4.31M
HSIC icon
47
Henry Schein
HSIC
$9.63B
$2.56M 0.57%
41,578
VEEV icon
48
Veeva Systems
VEEV
$29.2B
$2.43M 0.55%
27,200
-58,600
-68% -$5.35M
SYK icon
49
Stryker
SYK
$122B
$2.33M 0.52%
14,850
-500
-3% -$83.6K
FTV icon
50
Fortive
FTV
$18.5B
$2.2M 0.49%
+51,517
New +$2.42M

Similar funds

De Burlo Group's Q4 2018 Portfolio in Review

As of Q4 2018, De Burlo Group held 123 positions worth $445M, down 16% from $533M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

De Burlo Group withdrew a net $104M in Q4 2018, closing 33 positions and reducing 43 holdings. Its most notable exit was Atlassian, an estimated $15M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 27% of assets, down from 29% a quarter earlier, followed by Financials and Technology.

Against the trend, De Burlo Group opened a new position in Merck worth $11.7M.

  • De Burlo Group's largest Q4 2018 buy was Merck: 160,239 shares worth $11.7M.
  • De Burlo Group added most to Procter & Gamble in Q4 2018, an estimated $12.7M increase.
  • De Burlo Group's biggest Q4 2018 reduction was Amazon, cutting an estimated $8.98M.
  • De Burlo Group fully exited Atlassian in Q4 2018, selling an estimated $15M.
  • De Burlo Group's ten largest holdings make up 45% of its $445M portfolio in Q4 2018.
  • De Burlo Group opened 13 new positions and closed 33 in Q4 2018.
  • De Burlo Group's portfolio value fell 16% quarter-over-quarter to $445M.

Based on De Burlo Group's 13F filing for Q4 2018, filed 7 Feb 2019.